Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress. PR Newswire.

Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...

This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of CMV infection in solid organ transplant recipients.

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

Miracle drug’ can cost Rs 13 lakh for haemophilia A patient annually, but reduced dose found efficacious & cost-effective in ...

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Up to six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if vital ...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and ...